{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:25:00Z","timestamp":1762104300350,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100021564","name":"Unicancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.bulcan.2019.04.013","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T11:12:05Z","timestamp":1561461125000},"page":"759-775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Int\u00e9r\u00eats et limites de la recherche du d\u00e9ficit en dihydropyrimidine d\u00e9shydrog\u00e9nase dans le suivi des patients trait\u00e9s par fluoropyrimidines\u00a0: r\u00e9sultats de deux enqu\u00eates nationales de pratiques r\u00e9alis\u00e9es aupr\u00e8s des m\u00e9decins et des biologistes"],"prefix":"10.1016","volume":"106","author":[{"given":"Marie-Anne","family":"Loriot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadil","family":"Masskouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Carni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Legoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-7095","authenticated-orcid":false,"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Faroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-9165","authenticated-orcid":false,"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Malka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Guigay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4755-496X","authenticated-orcid":false,"given":"Juliette","family":"Thariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Barin-Le-Guellec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-311X","authenticated-orcid":false,"given":"Marie-Christine","family":"\u00c9tienne-Grimaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2018","series-title":"Recherche de d\u00e9ficit en dihydropyrimidine d\u00e9shydrogenase en vue de pr\u00e9venir certaines toxicit\u00e9s s\u00e9v\u00e8res survenant sous traitement comportant des fluoropyrimidines (5-fluorouracile). Recommandations et r\u00e9f\u00e9rentiels, INCa, HAS","key":"10.1016\/j.bulcan.2019.04.013_bib0130"},{"issue":"15","key":"10.1016\/j.bulcan.2019.04.013_bib0135","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1200\/JCO.2003.10.065","article-title":"Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24\u00a0or 36\u00a0weeks as adjuvant therapy in stages II and III colon cancer: results of a randomized trial","volume":"21","author":"Andre","year":"2003","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2019.04.013_bib0140","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2019.04.013_bib0145","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(14)70227-X","article-title":"Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3\u00a0trial","volume":"15","author":"Taieb","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2019.04.013_bib0150","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","article-title":"Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2\u00a0study, systematic review, and meta-analysis","volume":"32","author":"Rosmarin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2019.04.013_bib0155","doi-asserted-by":"crossref","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DPYD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bulcan.2019.04.013_bib0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminoncol.2017.02.008","article-title":"Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach","volume":"44","author":"Boisdron-Celle","year":"2017","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.04.013_bib0165","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett"},{"issue":"18","key":"10.1016\/j.bulcan.2019.04.013_bib0170","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","article-title":"Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.bulcan.2019.04.013_bib0175","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.04.013_bib0180","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/2212697X04666170817123425","article-title":"Upfront DPD deficiency detection to secure 5-FU administration: part 2-application to head-and-neck cancer patients","volume":"4","author":"Launay","year":"2017","journal-title":"Clin Cancer Drugs"},{"issue":"4","key":"10.1016\/j.bulcan.2019.04.013_bib0185","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","article-title":"Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity","volume":"313","author":"Tuchman","year":"1985","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2019.04.013_bib0190","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2019.04.013_bib0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2019.04.013_bib0200","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2019.04.013_bib0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2018.11.010","article-title":"A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy","volume":"107","author":"Henricks","year":"2019","journal-title":"Eur J Cancer"},{"year":"2018","series-title":"Xeloda. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit: EMA","author":"European Medicines Agency","key":"10.1016\/j.bulcan.2019.04.013_bib0210"},{"issue":"4","key":"10.1016\/j.bulcan.2019.04.013_bib0215","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2019.04.013_bib0220","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017\u00a0update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bulcan.2019.04.013_bib0225","unstructured":"Available from URL: https:\/\/www.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Prevention-des-effets-indesirables-graves-lies-a-un-deficit-en-dihydropyrimidine-deshydrogenase-DPD-lors-de-traitement-par-fluoropyrimidines-5-fluorouracile-et-capecitabine-Point-d-information-actualise-au-28-fevrier-2018."},{"year":"2019","series-title":"\u00ab\u00a0Cancer du c\u00f4lon non m\u00e9tastatique\u00a0\u00bb Th\u00e9saurus National de Canc\u00e9rologie Digestive","author":"Lecomte","key":"10.1016\/j.bulcan.2019.04.013_bib0230"},{"year":"2019","series-title":"\u00ab\u00a0Cancer colorectal m\u00e9tastatique\u00a0\u00bb. Th\u00e9saurus National de Canc\u00e9rologie Digestive","author":"Phelip","key":"10.1016\/j.bulcan.2019.04.013_bib0235"},{"issue":"8","key":"10.1016\/j.bulcan.2019.04.013_bib0240","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2019.04.013_bib0245","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2013.172","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing","volume":"94","author":"Caudle","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bulcan.2019.04.013_bib0125","unstructured":"Available from URL: http:\/\/www.asqualab.com\/index.html."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119302255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119302255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:19:57Z","timestamp":1762103997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455119302255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0007455119302255"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.04.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Int\u00e9r\u00eats et limites de la recherche du d\u00e9ficit en dihydropyrimidine d\u00e9shydrog\u00e9nase dans le suivi des patients trait\u00e9s par fluoropyrimidines\u00a0: r\u00e9sultats de deux enqu\u00eates nationales de pratiques r\u00e9alis\u00e9es aupr\u00e8s des m\u00e9decins et des biologistes","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}